title: [The combination of dasatinib and gefitinib enhances the killing effect of gefitinib on HCC827 lung cancer cells].
abstract: OBJECTIVE
  To investigate the molecular mechanism underlying that dasatinib enhances the killing effect of gefitinib on HCC827 lung cancer cells.
  
  
  METHODS
  HCC827 cells and gefitinib-resistant HCC827GR cells were treated with 0, 100, 500, 1000 nmol/L gefitinib alone or in combination with 1000 nmol/L dasatinib. The proliferation of HCC827 cells and HCC827GR cells was detected by MTT assay, the activity of caspase 3 was tested by spectrophotometry, and the protein phosphorylation levels of Src and epidermal growth factor receptor (EGFR) were examined by Western blotting.
  
  
  RESULTS
  Src phosphorylation level was obviously enhanced in HCC827GR cells. Dasatinib significantly inhibited Src phosphorylation, promoted the cell proliferation and the expression of caspase 3. The combination of gefitinib and dasatinib had the stronger killing effect than gefitinib alone did.
  
  
  CONCLUSIONS
  The combination of dasatinib and gefitinib can enhance the inhibition on the expression of Src protein and the killing effect of gefitinib on HCC827 lung cancer cells.
authors.affiliation: Chinese PLA Postgraduate Medical School, No.301 Hospital of PLA, Beijing 100853; Department of Cardiothoracic Surgery, No.306 Hospital of PLA, Beijing 100101, China.
authors.forename: Zhihong
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Department of Cardiothoracic Surgery, No.306 Hospital of PLA, Beijing 100101, China.
authors.forename: Lu
authors.initials: L
authors.lastname: Li
authors.affiliation: Department of Cardiothoracic Surgery, No.306 Hospital of PLA, Beijing 100101, China.
authors.forename: Zhuang
authors.initials: Z
authors.lastname: Shao
authors.affiliation: Department of Cardiothoracic Surgery, No.306 Hospital of PLA, Beijing 100101, China.
authors.forename: Huajie
authors.initials: H
authors.lastname: Xie
authors.affiliation: Department of Cardiothoracic Surgery, No.306 Hospital of PLA, Beijing 100101, China.
authors.forename: Fan
authors.initials: F
authors.lastname: Yang
authors.affiliation: Chinese PLA Postgraduate Medical School, No.301 Hospital of PLA, Beijing 100853, China. *Corresponding author, E-mail: wzhih@163.com.
authors.forename: Naikang
authors.initials: N
authors.lastname: Zhou
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D053148:Caspase 3 / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D000069439:Dasatinib / Q000494:pharmacology*; D004357:Drug Synergism; D066246:ErbB Receptors / Q000032:analysis; D000077156:Gefitinib; D006801:Humans; D010766:Phosphorylation; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011799:Quinazolines / Q000494:pharmacology*; D019061:src-Family Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D066246:ErbB Receptors; D019061:src-Family Kinases; D053148:Caspase 3; D000069439:Dasatinib; D000077156:Gefitinib